Dec 9 (Reuters) -
* AstraZeneca says Tagrisso reduced risk of disease progression by 70 percent and improved progression-free survival by almost six months
* AstraZeneca says data showed Tagrisso offered a statistically-significant improvement in PFS versus standard platinum-based doublet chemotherapy
* Reports data from Aura3 Phase III trial on Tagrisso Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.